英硅智能(03696)与保瑞宣布一项战略联盟推进人工智能驱动的药物研发

智通财经07-15 08:13

智通财经APP讯，英硅智能(03696)发布公告，英硅智能与全球制药制造领域领导者保瑞药业股份有限公司(保瑞;台湾证券交易所：6472;OTCQX：BORAY)宣布一项多面向战略联盟。该联盟将为广泛的、多面向合作框架奠定基础，具体合作内容须待双方进一步讨论并签署最终协议。若全面实施，拟议合作的潜在价值有望超过25亿美元。

该联盟下拟议合作将由英硅智能与保瑞通过后续协商并签署最终协议予以约定，其旨在整合英硅智能自有Pharma.AI平台在靶点发现、生成化学和分子优化等方面的技术优势，以及保瑞在全球药物开发、制造、品质管理和商业化领域的专业能力。透过打通AI赋能的研发体系与自动化驱动的开发、制造及品质执行流程，英硅智能与保瑞旨在共同开创新一代药物创新模式，衔接新颖分子的设计与开发、制造并向未满足医疗需求的患者交付药物所需的能力。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651871304?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 08:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651871304","market":"sh","top_or_hot":-1,"title":"英硅智能(03696)与保瑞宣布一项战略联盟 推进人工智能驱动的药物研发","media":"智通财经","content":"<html><body><p>智通财经APP讯，英硅智能(03696)发布公告，英硅智能与全球制药制造领域领导者保瑞药业股份有限公司(保瑞;台湾证券交易所：6472;OTCQX：BORAY)宣布一项多面向战略联盟。该联盟将为广泛的、多面向合作框架奠定基础，具体合作内容须待双方进一步讨论并签署最终协议。若全面实施，拟议合作的潜在价值有望超过25亿美元。</p><p>该联盟下拟议合作将由英硅智能与保瑞通过后续协商并签署最终协议予以约定，其旨在整合英硅智能自有Pharma.AI平台在靶点发现、生成化学和分子优化等方面的技术优势，以及保瑞在全球药物开发、制造、品质管理和商业化领域的专业能力。透过打通AI赋能的研发体系与自动化驱动的开发、制造及品质执行流程，英硅智能与保瑞旨在共同开创新一代药物创新模式，衔接新颖分子的设计与开发、制造并向未满足医疗需求的患者交付药物所需的能力。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英硅智能(03696)与保瑞宣布一项战略联盟 推进人工智能驱动的药物研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英硅智能(03696)与保瑞宣布一项战略联盟 推进人工智能驱动的药物研发\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，英硅智能(03696)发布公告，英硅智能与全球制药制造领域领导者保瑞药业股份有限公司(保瑞;台湾证券交易所：6472;OTCQX：BORAY)宣布一项多面向战略联盟。该联盟将为广泛的、多面向合作框架奠定基础，具体合作内容须待双方进一步讨论并签署最终协议。若全面实施，拟议合作的潜在价值有望超过25亿美元。</p><p>该联盟下拟议合作将由英硅智能与保瑞通过后续协商并签署最终协议予以约定，其旨在整合英硅智能自有Pharma.AI平台在靶点发现、生成化学和分子优化等方面的技术优势，以及保瑞在全球药物开发、制造、品质管理和商业化领域的专业能力。透过打通AI赋能的研发体系与自动化驱动的开发、制造及品质执行流程，英硅智能与保瑞旨在共同开创新一代药物创新模式，衔接新颖分子的设计与开发、制造并向未满足医疗需求的患者交付药物所需的能力。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1467599.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPNQ","symbol_name":"Calamos Nasdaq-100 Structured Alt Protection ETF - December","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1467599.html","article_id":"2651871304","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651871304","pubTimestamp":1784074435,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，英硅智能 发布公告，英硅智能与全球制药制造领域领导者保瑞药业股份有限公司宣布一项多面向战略联盟。透过打通AI赋能的研发体系与自动化驱动的开发、制造及品质执行流程，英硅智能与保瑞旨在共同开创新一代药物创新模式，衔接新颖分子的设计与开发、制造并向未满足医疗需求的患者交付药物所需的能力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161631":"人工智能","CPNQ":"Calamos Nasdaq-100 Structured Alt Protection ETF - December","TQQY":"GraniteShares YieldBOOST QQQ ETF","07522":"FI二华夏纳一百","03696":"英矽智能","NBDS":"NEUBERGER BERMAN DISRUPTERS ETF","09086":"华夏纳指-U","AIBU":"Direxion Daily AI and Big Data Bull 2X Shares","NOCT":"Innovator Growth-100 Power Buffer ETF - October","QMAR":"FT Vest Nasdaq-100 Buffer ETF - March","07568":"FI二南方纳指","NEWZ":"StockSnips AI-Powered Sentiment US All Cap ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","NAPR":"Innovator Growth-100 Power Buffer ETF - April","QLD":"2倍做多纳斯达克100指数ETF-ProShares","09834":"安硕纳指一百—U","QQQM":"NASDAQ100指数ETF-Invesco","OGIG":"ALPS O'Shares Global Internet Giants ETF","AIFD":"TCW Artificial Intelligence ETF","03086":"华夏纳指","PSQ":"做空纳斯达克100指数ETF-ProShares","QDEC":"FT Vest Nasdaq-100 Buffer ETF - December","KOMP":"SPDR S&P Kensho New Economies Composite ETF","QQA":"Invesco QQQ Income Advantage ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","LCLG":"Logan Capital Broad Innovative Growth ETF","GK":"AdvisorShares Gerber Kawasaki ETF","VUSE":"Vident U.S. Equity Strategy ETF","QQQX":"Nuveen NASDAQ 100 Dynamic Overwrite","AGIX":"通用人工智能 ETF-AGIX","QQQ":"纳指100ETF","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","03034":"南方纳指一百","07261":"华夏两倍做多纳斯达克100","NJUL":"Innovator Growth-100 Power Buffer ETF - July","FWD":"AB DISRUPTORS ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","NJAN":"Innovator Growth-100 Power Buffer ETF - January","BK4593":"纳斯达克ETF","MVPS":"Amplify Thematic All-Stars ETF","02834":"安硕纳指一百","QSWN":"Amplify BlackSwan Growth & Treasury Core ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October","03455":"景顺QQQ","TQQQ":"纳指三倍做多ETF","SQQQ":"纳指三倍做空ETF","07266":"南方两倍做多纳指","TARK":"Tradr 2X Long Innovation ETF","BK1141":"生命科学工具和服务"},"translate_title":"Insilicon Intelligent (03696) and Poly announce a strategic alliance to advance AI-driven drug research and development","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/0f33dd8d93019a9a1254373ff32ccb92","symbols_score_info":{"161631":1.5,"CPNQ":1.5,"07522":0.6,"NAPR":0.6,"QQQM":0.6,"QSWN":1.5,"GPIQ":0.6,"NJAN":0.6,"03696":1.5,"QLD":0.6,"TQQY":0.6,"PSQ":0.6,"QMAR":0.6,"VUSE":1.5,"OGIG":1.5,"FWD":1.5,"QTOC":1.5,"QQQ":0.6,"GK":1.5,"NBDS":1.5,"03034":0.6,"03086":0.6,"TARK":1.5,"MVPS":1.5,"SQQQ":0.6,"07568":0.6,"AIBU":1.5,"NOCT":0.6,"07261":0.6,"ARTY":1.5,"AIFD":1.5,"02834":0.6,"KOMP":1.5,"07266":0.6,"CHAT":1.5,"NEWZ":1.5,"09086":0.6,"QQQX":0.6,"QQA":1.5,"03455":0.6,"QDEC":0.6,"NJUL":0.6,"09834":0.6,"QID":1.5,"LCLG":1.5,"AGIX":1.5,"TQQQ":0.6},"content_text":"智通财经APP讯，英硅智能(03696)发布公告，英硅智能与全球制药制造领域领导者保瑞药业股份有限公司(保瑞;台湾证券交易所：6472;OTCQX：BORAY)宣布一项多面向战略联盟。该联盟将为广泛的、多面向合作框架奠定基础，具体合作内容须待双方进一步讨论并签署最终协议。若全面实施，拟议合作的潜在价值有望超过25亿美元。该联盟下拟议合作将由英硅智能与保瑞通过后续协商并签署最终协议予以约定，其旨在整合英硅智能自有Pharma.AI平台在靶点发现、生成化学和分子优化等方面的技术优势，以及保瑞在全球药物开发、制造、品质管理和商业化领域的专业能力。透过打通AI赋能的研发体系与自动化驱动的开发、制造及品质执行流程，英硅智能与保瑞旨在共同开创新一代药物创新模式，衔接新颖分子的设计与开发、制造并向未满足医疗需求的患者交付药物所需的能力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651871304","isCrawlerRequest":true}